Re: “Evolution of low HER2 expression between early and advanced-stage breast cancer”

In a phase 3, multicentre, open-label, randomised trial, trastuzumab deruxtecan (TD) was superior to the standard of care trastuzumab emtansine in patients with HER2-positive metastatic breast cancer (mBC) previously treated with trastuzumab and a taxane [1]. Then, a phase 3 trial with HER2-low mBC patients (defined as 1+ and 2+ by immunohistochemistry [IHC] or negative by in situ hybridisation [ISH]) who had received previous lines of chemotherapy was performed [2]. In this trial TD resulted in significantly longer progression-free and overall survival than the physician’s choice of chemotherapy.

Lascia un commento